Discover
MTSR
Metsera, Inc.
70.50
2 x 50.92
2 x 90.56
bid
ask
-
0.25
0.35%
04:00 PM
| Ytd | 0.00% | |
| 1y | 0.00% |
70.13
day range
70.76
12.30
52 week range
83.86
| Open | 70.74 | Prev Close | 70.75 | Low | 70.13 | High | 70.76 | Mkt Cap | 7.43B |
| Vol | 27.87M | Avg Vol | 3.50M | EPS | -2.99 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | 2.52 | Inst. Own | 90.24% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 03-25 | 50-d Avg | 53.47 | 200-d Avg | 35.09 | 1yr Est | 57.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2025-11-12 | 2025-09 | 0 | N/A | N/A | N/A |
| 2025-07-28 | 2025-06 | 0 | N/A | N/A | N/A |
| 2025-05-12 | 2025-03 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2025-09-24 | Leerink Partners | Downgrade | Outperform | Market Perform |
| 2025-09-09 | Leerink Partners | Upgrade | Outperform | |
| 2025-09-03 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
| 2025-08-28 | B of A Securities | Upgrade | Buy | Buy |
| 2025-06-20 | Wells Fargo | Upgrade | Overweight | |
| 2025-06-10 | Guggenheim | Upgrade | Buy | Buy |
Profile
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, New York. As of November 13, 2025, Metsera, Inc. operates as a subsidiary of Pfizer Inc.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-02-02 | ARCH VENTURE PARTNERS XII, LLC | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2025-02-02 | BERNS PAUL L | Director | 0.00 | Purchase |
| 2025-02-02 | BUROW KRISTINA M | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2025-11-09 | FMR LLC | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Stock Gift |
| 2025-01-29 | WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS CAYMAN II | Beneficial Owner of more than 10% of a Class of Security | 1.86M | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-09-29 | FMR, LLC | 13.89M | 979.39M | 13.18% |
| 2025-09-29 | Vanguard Group Inc | 5.82M | 410.66M | 5.53% |
| 2025-09-29 | Janus Henderson Group PLC | 5.35M | 377.37M | 5.08% |
| 2025-09-29 | Blackrock Inc. | 3.84M | 270.39M | 3.64% |
| 2025-09-29 | Alphabet Inc. | 3.78M | 266.74M | 3.59% |
| 2025-09-29 | VR Adviser, LLC | 3.75M | 264.42M | 3.56% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-09-29 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 3.63M | 255.90M | 3.44% |
| 2025-07-30 | VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 2.11M | 148.50M | 2.00% |
| 2025-09-29 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.00M | 140.90M | 1.90% |
| 2025-09-29 | VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.50M | 105.41M | 1.42% |
| 2025-09-29 | SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF | 1.34M | 94.21M | 1.27% |
| 2025-09-29 | iShares Trust-iShares Russell 2000 ETF | 1.32M | 93.34M | 1.26% |